270 related articles for article (PubMed ID: 27989651)
1. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin promotes osteoblastic MC3T3-E1 differentiation
Song P; Chen T; Rui S; Duan X; Deng B; Armstrong DG; Ma Y; Deng W
Front Endocrinol (Lausanne); 2022; 13():1081039. PubMed ID: 36589840
[TBL] [Abstract][Full Text] [Related]
6. Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.
Trentin-Sonoda M; Cheff V; Gutsol A; Hébert RL
PLoS One; 2023; 18(12):e0295284. PubMed ID: 38055691
[TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
10. GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM.
Argento NB; Nakamura K
Endocr Pract; 2016 Mar; 22(3):315-22. PubMed ID: 26523624
[TBL] [Abstract][Full Text] [Related]
11. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Garrett K; Popescu I; Pennings JS; Fowlkes JL; Nyman JS
Bone; 2020 Apr; 133():115254. PubMed ID: 31991250
[TBL] [Abstract][Full Text] [Related]
12. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
13. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
Rodbard HW; Peters AL; Slee A; Cao A; Traina SB; Alba M
Diabetes Care; 2017 Feb; 40(2):171-180. PubMed ID: 27899497
[TBL] [Abstract][Full Text] [Related]
15. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Jackson K; Moseley KF
Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway.
Huang S; Wu B; He Y; Qiu R; Yang T; Wang S; Lei Y; Li H; Zheng F
Hepatol Commun; 2023 Mar; 7(3):e0045. PubMed ID: 36757426
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin Prevents Hyperglycemia-Associated Muscle Extracellular Matrix Accumulation and Improves the Adaptive Response to Aerobic Exercise.
MacDonald TL; Pattamaprapanont P; Cooney EM; Nava RC; Mitri J; Hafida S; Lessard SJ
Diabetes; 2022 May; 71(5):881-893. PubMed ID: 35108373
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Miyata KN; Zhao S; Wu CH; Lo CS; Ghosh A; Chenier I; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
Diabetes Res Clin Pract; 2020 Apr; 162():108107. PubMed ID: 32173417
[TBL] [Abstract][Full Text] [Related]
20. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
